Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

被引：0

作者：

Pro, Barbara ^{[1
]}

Advani, Ranjana H. ^{[2
]}

Brice, Pauline ^{[3
]}

Bartlett, Nancy L. ^{[4
]}

Rosenblatt, Joseph D. ^{[5
]}

Illidge, Tim ^{[6
]}

Matous, Jeffrey V. ^{[7
]}

Ramchandren, Radhakrishnan ^{[8
]}

Fanale, Michelle A. ^{[9
]}

Connors, Joseph M. ^{[10
]}

Yang, Yin ^{[11
]}

Kennedy, Dana A. ^{[11
]}

Shustov, Andrei R. ^{[12
]}

机构：

[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[2] Stanford Univ, Med Ctr, Stanford, CA 94305 USA

[3] Hosp St Louis, Paris, France

[4] Washington Univ, Sch Med, St Louis, MO USA

[5] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[6] Christie Hosp NHS, Manchester, Lancs, England

[7] Colorado Blood Canc Inst, Denver, CO USA

[8] Karmanos Canc Inst, Detroit, MI USA

[9] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[10] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC V5Z 4E6, Canada

[11] Seattle Genet Inc, Bothell, WA USA

[12] Univ Washington, Med Ctr, Seattle, WA 98195 USA

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.2745.2745

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2745

引用

页数：2

共 50 条

[1] Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Shustov, Andrei R.
Advani, Ranjana
Brice, Pauline
Bartlett, Nancy L.
Rosenblatt, Joseph D.
Illidge, Tim
Matous, Jeffrey
Ramachandren, Radhakrishnan
Fanale, Michelle A.
Connors, Joseph M.
Yang, Yin
Sievers, Eric L.
Kennedy, Dana A.
Pro, Barbara
BLOOD, 2010, 116 (21) : 423 - 424
[2] Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma
Chen, Robert W.
Gopal, Ajay K.
Smith, Scott E.
Ansell, Stephen M.
Rosenblatt, Joseph D.
Savage, Kerry J.
Connors, Joseph M.
Engert, Andreas
Larsen, Emily K.
Sievers, Eric L.
Younes, Anas
BLOOD, 2012, 120 (21)
[3] Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma
Pro, Barbara
Advani, Ranjana H.
Brice, Pauline
Bartlett, Nancy L.
Rosenblatt, Joseph D.
Illidge, Tim
Matous, Jeffrey
Ramchandren, Radhakrishnan
Fanale, Michelle A.
Connors, Joseph M.
Yang, Yin
Huebner, Dirk
Kennedy, Dana A.
Shustov, Andrei R.
BLOOD, 2013, 122 (21)
[4] DURABLE REMISSIONS WITH SGN-35 (BRENTUXIMAB VEDOTIN): UPDATED RESULTS OF A PHASE 2 STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (SALCL)
Shustov, A.
Advani, R.
Brice, P.
Bartlett, N. L.
Rosenblatt, J. D.
Illidge, T.
Matous, J.
Ramchandren, R.
Fanale, M.
Connors, J. M.
Yang, Y.
Sievers, E. L.
Kennedy, D. A.
Pro, B.
ANNALS OF ONCOLOGY, 2011, 22 : 125 - 125
[5] Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update
Advani, Ranjana H.
Shustov, Andrei R.
Brice, Pauline
Bartlett, Nancy L.
Rosenblatt, Joseph D.
Illidge, Tim
Matous, Jeffrey
Ramchandren, Radhakrishnan
Fanale, Michelle A.
Connors, Joseph M.
Yang, Yin
Kennedy, Dana A.
Pro, Barbara
BLOOD, 2011, 118 (21) : 204 - 204
[6] Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Pro, Barbara
Advani, Ranjana
Brice, Pauline
Bartlett, Nancy L.
Rosenblatt, Joseph D.
Illidge, Tim
Matous, Jeffrey
Ramchandern, Radhakrishnan
Fanale, Michelle A.
Connors, Joseph M.
Wang, Yinghui
Huebner, Dirk
Kennedy, Dana A.
Shustov, Andrei R.
BLOOD, 2014, 124 (21)
[7] Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma
Zinzani, Pier Luigi
Gandolfi, Letizia
Casadei, Beatrice
Pellegrini, Cinzia
Broccoli, Alessandro
Derenzini, Enrico
Quirini, Federica
Tonialini, Lorenzo
Cavo, Michele
Argnani, Lisa
Stefoni, Vittorio
BLOOD, 2015, 126 (23)
[8] LONG-TERM RESPONDERS AFTER BRENTUXIMAB VEDOTIN: EXPERIENCE ON 57 PATIENTS WITH RELAPSED AND REFRACTORY HODGKIN AND ANAPLASTIC LARGE CELL LYMPHOMA
Gandolfi, L.
Celli, M.
Pellegrini, C.
Casadei, B.
Morigi, A.
Stefoni, V.
Broccoli, A.
Quirini, F.
Tonialini, L.
Argnani, L.
Cavo, M.
Zinzani, P. L.
HAEMATOLOGICA, 2015, 100 : 3 - 3
[9] Relapsed or refractory anaplastic large cell lymphoma: Brentuximab vedotin of course!
Paillassa, Jerome
HEMATOLOGIE, 2018, 24 (01): : 19 - 21
[10] Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma
Lai, Chao-Ming
Horowitz, Sandra
EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (04) : 361 - 373

← 1 2 3 4 5 →